Form 4: Actuate Therapeutics: Insider Ownership Update Fletcher and BIOS Equity Partners Report Beneficial Ownership

Aaron G.L. Fletcher, a director and 10% owner of Actuate Therapeutics, along with related entities under BIOS Equity Partners, reported changes in beneficial ownership of the company's common stock.

Summary

• This Form 4 filing reports changes in beneficial ownership of Actuate Therapeutics, Inc. (ACTU) common stock by Aaron G.L. Fletcher, who is a director and 10% owner, and related entities under BIOS Equity Partners.
• The reported ownership includes shares held directly and indirectly through various entities such as BP Directors, LP, KF Legacy Trust, MF Legacy Trust, and Circle K Invesco, LP.
• The filing is one of six Forms 4 filed relating to the same event, split due to SEC EDGAR system limitations on the number of reporting persons and rows.
• Other reporting persons, besides Leslie W. Kreis, may be deemed 'director by deputization' due to Aaron G.L. Fletcher's position as a director of the Issuer.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports changes in ownership.

Industry Context

This filing is a routine disclosure of insider ownership changes, which is common in publicly traded companies. It provides transparency into the holdings of directors and significant shareholders.

Stakeholder Impact

• The filing provides shareholders with information about the ownership structure of the company.
• It may influence investor perception of the company based on the actions of significant shareholders.

Key Dates